Shots:

• AbbVie in collaboration with Adaptive evaluate depth and duration of response to venetoclax and measure minimal residual disease (MRD) status in MM treated patients utilizing Adaptive’s next-generation sequencing (NGS)-based clonoSEQ assay
• The partnership encourages the development & regulatory approval of venetoclax in MM and the increasing use of clonoSEQ in drug development as a method to assess response to new therapies
• Venetoclax is a first-in-class small molecule selective BCL-2 inhibitor being evaluated in studies for MM patients while clonoSEQ is the first and only FDA authorized MRD test to monitor MRD in MM and B-cell ALL using DNA from bone marrow samples

  Ref: PRNewswire | Image: PRNewswire